首页> 外文OA文献 >LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

【2h】

LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

机译：LBA53针对PD1 / L1免疫检查点抑制剂（ICIS）处理的先进非小细胞肺癌（NSCLC）患者（PTS）的LBA53精确免疫肿瘤（PTS）：首次分析先驱研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
F. Barlesi; L. Greillier; F. Monville; C. Foa; C. Audigier-Valette; F. Vély; S. Garcia; F. Sabatier; J. Ciccolini; M. Fabre; M. Le Ray; N. Resseguier; P. Outters; M. Roumieux; J. Mazieres; M. Pérol; E. Vivier; P. Auquier; J. Fieschi;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients [J] . L. Hendriks, C. Henon, E. Auclin, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018 ,第10期

机译：MA08.09脑转移在免疫检查点抑制剂中的影响（ICI）治疗的晚期非小细胞肺癌（NSCLC）患者
2. P2.04-28 Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS) [J] . J. Thompson, C. Arce-Lara, S. Menon Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018 ,第10期

机译：P2.04-28免疫检查点抑制剂（ICIS）在难治性非小细胞肺癌（NSCLC）和性能状况不佳（PS）中的使用
3. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study [J] . Kaho Miura, Yoshiyuki Sano, Seiji Niho, Thoracic cancer. . 2021 ,第13期

机译：伴随药物对免疫检查点抑制剂治疗晚期非小细胞肺癌患者临床结果的影响：回顾性研究
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs) [O] . Ye Li, Zhibo Zhang, Yi Hu, 2020

机译：预处理中性粒细胞至淋巴细胞比率（NLR）可以预测用免疫检查点抑制剂（ICIS）治疗的晚期非小细胞肺癌（NSCLC）患者的结果
7. P1.04-30 Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance [O] . F. Barlesi, D. Pérol, J. Mazieres, 2019

机译：P1.04-30先锋研究：针对PD1 / L1 ICI抗性的先进非小细胞肺癌患者精密免疫肿瘤

LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

著录项

相似文献

相关主题

期刊订阅